Quantcast

Latest Oncotype DX Stories

2014-06-16 12:29:09

Approval to Begin Clinical Laboratory Operations in Support of PraediCare-Dx(TM) Portfolio CAMBRIDGE, Mass., June 16, 2014 /PRNewswire/ -- EUTROPICS Inc., a privately held company developing novel diagnostic tests that provide predictive insights to cancer patient response to treatment, today announced its laboratory, located in Cambridge, MA, has received Clinical Laboratory Improvement Amendment (CLIA) certification from the U.S. Department of Health and Human Services' Centers for...

2014-06-11 08:29:34

Complete Data to be Submitted for Presentation at the 2014 San Antonio Breast Cancer Symposium REDWOOD CITY, Calif., June 11, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced positive preliminary results from a second large, independent clinical validation study of Oncotype DX® in patients with a pre-invasive form of breast cancer, also known as DCIS (ductal carcinoma in situ). The study, conducted by the Ontario DCIS Study Group in Canada, met its primary...

2014-06-04 15:29:19

Albert Einstein College of Medicine The study was led by researchers at the National Cancer Institute (NCI)─designated Albert Einstein Cancer Center of Albert Einstein College of Medicine of Yeshiva University and Montefiore Einstein Center for Cancer Care and was published online today in the Journal of the National Cancer Institute (JNCI). "Tests assessing metastatic risk can help doctors identify which patients should receive aggressive therapy and which patients should be spared,"...

2014-06-03 16:24:50

BRONX, N.Y., June 3, 2014 /PRNewswire-USNewswire/ -- A test that counts the number of locations in tumor specimens where tumor cells may invade blood vessels predicted the risk of distant spread, or metastasis, for the most common type of breast cancer. http://photos.prnewswire.com/prnvar/20140603/93895 The study was led by researchers at the National Cancer Institute (NCI)?designated Albert Einstein Cancer Center of Albert Einstein College of Medicine of Yeshiva University and...

2014-06-03 08:32:24

Two Studies Presented at ASCO® Demonstrate Company's Ability to Develop Tests to Predict Disease Aggressiveness Across Various Cancers REDWOOD CITY, Calif., June 3, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results of two studies demonstrating the ability of its Oncotype DX(®) test and a new 16-gene panel to predict disease aggressiveness and clinical outcomes in prostate and renal cancers, respectively. These results, presented at the American...

2014-06-01 08:20:43

New Study Shows Oncotype DX® DCIS Score(TM) Changes Treatment Recommendations for One Out of Three DCIS Patients REDWOOD CITY, Calif., June 1, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results of six studies being presented at the 2014 American Society of Clinical Oncology(®) (ASCO(®)) Annual Meeting taking place May 30 - June 3 in Chicago, underscoring the practice-changing value of Oncotype DX(®)( )in pre-invasive and invasive breast cancer and colon...

2014-05-29 08:29:37

New Data Presented at ASCO® Annual Meeting Suggest that Genomic Health's Oncotype DX Test May Help Identify Patients That Have the Greatest Opportunity to Benefit from Extended Hormonal Therapy REDWOOD CITY, Calif., May 29, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results of a large, positive study that confirmed that the Oncotype DX® test results for Recurrence Score® and quantitative estrogen-receptor (ER) predict late distant recurrence risk in...

2014-05-23 08:24:11

REDWOOD CITY, Calif., May 23, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that members of its management team will present at the following conferences in June: -- Jefferies 2014 Global Healthcare Conference on Monday, June 2 at 4:00 p.m. Eastern Time (ET) in New York City; and -- Goldman Sachs 35(th) Annual Global Healthcare Conference on Wednesday, June 11 at 2:00 p.m. Pacific Time (PT) in Rancho Palos Verdes, Calif....

2014-05-20 16:27:05

New Analysis Suggests Oncotype DX Predicts Recurrence Risk After Prostatectomy Regardless of Post-Surgery Treatment REDWOOD CITY, Calif., May 20, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today presented positive results reinforcing the robustness of the Oncotype DX(®) prostate cancer test's development as a predictor of prostate cancer aggressiveness. A sub-analysis of a large Oncotype DX Genomic Prostate Score (GPS) development study, presented at the American...

2014-05-16 16:24:58

Oncotype DX® Prostate Cancer Test Enables More Precise Risk Assessment and Significantly Increases Number of Low-Risk Patients Who Can Confidently Choose Active Surveillance REDWOOD CITY, Calif., May 16, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) announced today that groundbreaking results from three studies of the Oncotype DX(®) prostate cancer test were published in European Urology. The peer-reviewed publication highlights studies that focus on addressing the need...


Word of the Day
callithump
  • A somewhat riotous parade, accompanied with the blowing of tin horns, and other discordant noises; also, a burlesque serenade; a charivari.
'Callithump' is a back-formation of 'callithumpian,' a 'fanciful formation' according to the Oxford English Dictionary. However, the English Dialect Dictionary, says 'Gallithumpians' is a Dorset and Devon word from the 1790s that refers to 'a society of radical social reformers' or 'noisy disturbers of elections and meetings.'
Related